Hélène Ste-Croix

468 total citations
6 papers, 319 citations indexed

About

Hélène Ste-Croix is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Hélène Ste-Croix has authored 6 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Cancer Research, 2 papers in Pulmonary and Respiratory Medicine and 2 papers in Hepatology. Recurrent topics in Hélène Ste-Croix's work include Cancer, Hypoxia, and Metabolism (3 papers), Lung Cancer Treatments and Mutations (2 papers) and Hematopoietic Stem Cell Transplantation (1 paper). Hélène Ste-Croix is often cited by papers focused on Cancer, Hypoxia, and Metabolism (3 papers), Lung Cancer Treatments and Mutations (2 papers) and Hematopoietic Stem Cell Transplantation (1 paper). Hélène Ste-Croix collaborates with scholars based in Canada. Hélène Ste-Croix's co-authors include Jeffrey M. Besterman, Marielle Fournel, Claire Bonfils, Marie‐France Robert, Jinru Wang, Pu Yan, Zuomei Li, A. Robert MacLeod, Jeffrey Gillespie and Sylvain Lefèbvre and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Hélène Ste-Croix

6 papers receiving 310 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hélène Ste-Croix Canada	4	275	110	34	31	24	6	319
Marty J. Heslin United States	5	245 0.9×	104 0.9×	33 1.0×	16 0.5×	18 0.8×	7	329
Cornelia Meisenberg United Kingdom	9	371 1.3×	128 1.2×	19 0.6×	44 1.4×	18 0.8×	10	407
Duowei Wang China	9	174 0.6×	71 0.6×	12 0.4×	18 0.6×	81 3.4×	15	305
Manuel D. Haschka Austria	8	304 1.1×	123 1.1×	13 0.4×	14 0.5×	62 2.6×	10	397
Vithya Manoharan Singapore	3	256 0.9×	120 1.1×	19 0.6×	34 1.1×	10 0.4×	4	330
Monica Valenti Italy	8	238 0.9×	227 2.1×	10 0.3×	25 0.8×	16 0.7×	17	348
Stephanie B. Hatch United Kingdom	10	247 0.9×	128 1.2×	28 0.8×	74 2.4×	12 0.5×	12	361
Amr Mohamed Yehia Egypt	10	222 0.8×	47 0.4×	26 0.8×	22 0.7×	11 0.5×	11	338
Dana Ungermannova United States	10	358 1.3×	193 1.8×	53 1.6×	16 0.5×	8 0.3×	10	399

Countries citing papers authored by Hélène Ste-Croix

Since Specialization

Citations

This map shows the geographic impact of Hélène Ste-Croix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hélène Ste-Croix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hélène Ste-Croix more than expected).

Fields of papers citing papers by Hélène Ste-Croix

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hélène Ste-Croix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hélène Ste-Croix. The network helps show where Hélène Ste-Croix may publish in the future.

Co-authorship network of co-authors of Hélène Ste-Croix

This figure shows the co-authorship network connecting the top 25 collaborators of Hélène Ste-Croix. A scholar is included among the top collaborators of Hélène Ste-Croix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hélène Ste-Croix. Hélène Ste-Croix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

Bonfils, Claire, Normand Beaulieu, Marielle Fournel, et al.. (2012). Abstract 1790: The combination of MGCD265, a Met/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis. Cancer Research. 72(8_Supplement). 1790–1790. 13 indexed citations

Besterman, Jeffrey M., Marielle Fournel, Isabelle Dupont, et al.. (2010). Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib.. Journal of Clinical Oncology. 28(15_suppl). e13595–e13595. 17 indexed citations

Fournel, Marielle, Isabelle Dupont, Claire Bonfils, et al.. (2010). Abstract 3612: Potent preclinical anti-tumor activity of MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, in combination with an EGFR inhibitor. Cancer Research. 70(8_Supplement). 3612–3612. 3 indexed citations

Fournel, Marielle, Claire Bonfils, Yu Hou, et al.. (2008). MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Molecular Cancer Therapeutics. 7(4). 759–768. 271 indexed citations

Beaulieu, Nancy, Isabelle Dupont, Carole Beaulieu, et al.. (2008). 81 POSTER Preclinical pharmacodynamic markers of MGCD265, a potent orally active c-Met/VEGFR multitargeted kinase inhibitor in Phase I clinical trials. European Journal of Cancer Supplements. 6(12). 28–28. 3 indexed citations

Prud’homme, Gérald J., Renouard Sanders, Nollaig A. Parfrey, & Hélène Ste-Croix. (1991). T-cell maturation and clonal deletion in cyclosporine-induced autoimmunity. Journal of Autoimmunity. 4(2). 357–368. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact